25Sep

SpeeDx and Diagen sign new distribution agreement for Scandinavia

SYDNEY, AUSTRALIA – (Sept 19, 2017). SpeeDx Pty, Ltd. has announced a distribution agreement with Diagen, a leading Scandinavian clinical laboratory supplier specialising in diagnostic products. This agreement will open important sales channels in Sweden, Norway and Denmark for SpeeDx’s PlexPCR® and unique, multiplexed ResistancePlus® real-time polymerase chain reaction product lines.

Diagen has a strong reputation for providing advanced sales and support to hospitals, universities and research laboratories across Scandinavia. Using SpeeDx’s proprietary technology, the PlexPCR range will allow Diagen’s customers to obtain complex diagnostic information on sexually transmitted infections or other infectious diseases from a single, cost-effective test. The agreement will also give them access to the groundbreaking ResistancePlus MG assay. This is the first CE-IVD test to simultaneously detect Mycoplasma genitalium and genetic markers for azithromycin resistance, as recommended by the new European guidelines on M. genitalium resistance screening in the management of non-gonococcal urethritis.

“Scandinavia is home to some important thought leaders influencing sexual health and STI testing practices across Europe,” said Colin Denver, CEO of SpeeDx. “We see our partnership with Diagen as key to offering the best service to laboratories across these important markets.” 

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. Currently, SpeeDx markets the only CE-marked and TGA approved commercial molecular test for the STI M. genitalium (ResistancePlus™ MG) that combines detection of the disease with detection of markers for antibiotic resistance. For more information on about SpeeDx please see: http://plexpcr.com

About Diagen

Diagen AS is a supplier and consulting company within the laboratory field. In addition to our specialty in diagnostics and genetic engineering, we deliver advanced and fully automated instruments within routine diagnostics and life sciences across the Nordic region. The company operates consultancy, sales, marketing, technical service and support. The company markets products from reputable manufacturers worldwide.

Related

CRYOcheck™ - Reducing Errors for 25 Years

For 25 years Precision BioLogic’s CRYOcheck™ range of fresh frozen plasma reagents, calibrators an...

Read More >

EKF expands geographical reach of PCT test for early sepsis detection

Cardiff, UK – 2nd May 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces t...

Read More >

The TOPRA Annual Symposium

The TOPRA Annual Symposium is the largest forum for European regulatory professionals to meet up, di...

Read More >

OGT continues move into molecular diagnostics markets with MDSAP certification

Certification of new Cambridge facility smooths path to future IVD approvals

Read More >

Radiometer sponsors World Sepsis Day 2017

In continuation of Radiometer’s commitment to the fight against sepsis – one of the world’s deadl...

Read More >

BBI Solutions adds more antibodies to product range

BBI Solutions has continued to invest in its portfolio of antibodies and today announced the launch ...

Read More >